en

Pre-Plated Phenotypic Sets


Pre-Plated Sets: Format/Size Descriptions Download
Signature Libraries 5556 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2020-07
ASINEX's cutting edge chemistry combined with in silico and in vitro screening validation.
Macrocycle
Pre-Plated Set
25261 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2021-09
ASINEX ‘s Macrocycle Pre-plated Sets are designed to provide the most popular screening libraries in a convenient and cost-effective manner.
Diversity
Pre-Plated Set
72578 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2022-02
Pre-Plated Set of compounds selected from ASIENX BioDesign Libraries, Elite Libraries, Synergy Libraries, Gold&Platinum Collections.
PPI Pre-Plated Set 3743 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2020-07
ASINEX has been working on the design and synthesis of protein-protein interaction (PPI) libraries since 2008. The latest generation of ASINEX PPI Library comprises molecules of various sizes, frameworks, and shapes ranging from fragment-like entities to macrocyclic derivatives designed as secondary structure mimetics or as epitope mimetics.
CNS Diversity
Pre-Plated Set
6055 compounds
Pre-Plated Set
Amount: 0.01-2.0mg
Update: 2020-07
ASINEX has selected CNS-like molecules with high diversity:
CNS-MPO > 4
CNS-MPO.v2 > 4
CNS-TEMPO < 4
Glycomimetics
Pre-Plated Set
2430 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2020-07
ASINEX has overcome these obstacles by creating a glycomimetic library that ensures the bioactive function of carbohydrates while addressing the drawbacks of carbohydrates, such as their low activity and poor drug-like properties.
Nucleoside-mimetics
Pre-Plated Set
3542 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2022-02
ASINEX has developed a number of stereo- and enantio-selective methods for the synthesis of nucleoside-like core intermediates (e. g. mimics of adenosine). These unique intermediates have been extensively decorated by various long chain amines, acids and amino acids.
Kinase Pre-Plated Set 6493 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2020-07
ASINEX facilitates the discovery of novel kinase inhibitors by providing access to our advanced collection of small molecules, fragments and macrocycles. The efficacy of our compounds has been validated through in silico modeling and in vitro on-target and phenotypic profiling. This is paralleled with 20+ years of medicinal chemistry expertise, delivering designs with outstanding ADMET and PK properties, optimizing chances in hit to candidate development.
Covalent Inhibitors
Pre-Plated Set
988 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2020-07
ASINEX has crafted a unique set of 1000 molecules containing electophylic moieties that could potentially interact with cysteine residues in the target protein. The diversity of represented scaffolds creates multiple opportunities for drug discovery in various target and therapeutic areas such as kinases, proteases, protein-protein interactions, and antimicrobials.
Phenotypic Screening Sets: Format/Size Descriptions Download
Phenotypic
Pre-Plated Set
13159 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2020-07
ASINEX has created a diverse set of molecules by applying strict physico-chemical and structural descriptors to ensure good solubility and permeability properties.
Asinex in GOSTAR 1878 compounds
41742 analogues
For cherry-picking
Update: 2020-11
Asinex have opted to use the Global Online Structure Activity Relationship Database (GOSTAR) as an integrated source of data capturing chemical, biological, pharmacological, and therapeutic parameters. The structural overlap between the Asinex (500K+) and GOSTAR (8M+) databases has revealed 17910 unique molecules with associated biological activity. Application of additional structural filters (PAINS, Eli Lilly [4-5]) has resulted in a set of 11923 compounds; diversity-oriented selection supported by computational and medicinal chemistry expertise has further refined this set resulting in 1878 molecules available for computational or in vitro evaluation. Biological diversity is represented by multiple target families where each molecule is associated with a GOSTAR record via a unique structure code identifier. For more information, please download >>>
SL#004
Oncology
Phenotypic Screening-1
(Non-Macrocycle)
80 compounds / set
Pre-Plated Set
Update: 2016
ASINEX's oncology-oriented phenotypic library includes compounds based on several scaffolds with proven cytotoxicity (sub-µM EC50 in MTT assay) against a number of cancer cell lines: MV-411 (acute monocytic leukemia), HCT-116 (human colon cancer), MCF-7 (human breast adenocarcinoma‎), A-172 (Human glioblastoma), COLO-320 (colorectal adenocarcinoma), U-937 (histiocytic lymphoma), A-375 (malignant melanoma), BXPC-3 (pancreas adenocarcinoma), U118-MG (malignant glioma), and LN-229 (glioblastoma). Some active compounds were screened in a biochemical assay showing nM level of IC50 against several kinases: Aurora A, Haspin, VEGFR, EGFR, PDGFR.
SL#023
Oncology
Phenotypic Screening-2
(Colon Cancer
Non-Macrocycle)
80 compounds / set
Pre-Plated Set
Update: 2016
ASINEX has evaluated the susceptibility of several colon cancer cell lines (HCT-116, SW-620, COLO-320, RKO) to a diverse array of small molecules and identified a series of related compounds that kill cancer cells at sub-µM concentrations with limited off target effect on healthy cells (human fibroblasts). Additional screening in a cell-based luciferase reporter assay of Wnt signaling has provided preliminary evidence of Wnt-dependent mechanism of action.
SL#035
Oncology
Phenotypic Screening-3
(Macrocycles)
80 compounds / set
Pre-Plated Set
Update: 2016
ASINEX has evaluated the susceptibility of several cancer cell lines (i.e. RKO, HCT116, Molt-4, Rs4-11, U937, A549, H1568, H23, PANC1, A2780) to an array of peptidic and non-peptidic macrocycles and identified a series of compounds that kill cancer cells at µM concentrations.
Contact
Global

Ludmila Sadovenko

lsadovenko@asinex.com
North America

Mark Parisi

mparisi@asinex.com

Toll Free: +1 877 ASINEX1

Tel: +1 336 721 1617

Fax: +1 336 721 1618

N.Chestnut St., Ste.104

Winston-Salem, NC 27101

USA

Europe

Galina Afanasyeva

gafanasyeva@asinex.com

Tel: +31 (0) 203416183

Klaprozenweg 75C, 1033NN

Amsterdam, The Netherlands

Japan

Shingo Ota

sota@asinex.com

Tel: 080-3401-9097

30-2 Higashihazu, Nishio,

Aichi Japan

Cart
Your cart is empty
Order
$
0
Checkout
Thanks for your order
We will contact you shortly